United Kingdom (UK)
Recombinant monoclonal antibody to digoxin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1B3.
Alternative Name(s) of Target: 12β-hydroxydigitoxin; digitalis; 12-beta-hydroxydigitoxin
Immunogen: This antibody was raised using transgenic HC2/KCo5 mice with the humanised humoral immune system capable of generating human IgG1 κ Abs.The mice were immunised with digoxin conjugated to keyhole limpet hemocyanin (KLH).
Specificity: 1B3 antibody recognises digoxin and digitoxin with an excellent binding affinity of Kd = 3 and 0.6 nM, respectively. Digoxin and digitoxin are both cardiac glycosides used widely in cardiology to treat various heart conditions, such as heart failure.
Application Notes: Digoxin is widely used in various heart conditions. However, the drug has a very narrow therapeutic index and can cause toxic side effects. The antibody might neutralise the activity of digoxin and could be used as an antidote in case of overdose of digitalis (Paula et al., 2005). It is additionally superior to the widely utilised Fab preparations of sheep polyclonal anti-digoxin Abs as it is a humanised antibody which will not activate the immune system in patients (Ball et al., 1999). Anti-digoxin monoclonal antibodies can also be used to measure serum levels of the drug as a guide to therapy, and are useful in the investigation of the kinetics of interaction between antibody and antigen.
Antibody first published in:
Ball et al. Isolation and characterization of human monoclonal antibodies to digoxin. J Immunol. 1999 Aug 15;163(4):2291-8. PMID:10438974
Note on publication:
This article describes the generation and characterisation of human anti-digoxin mAbs raised in transgenic mice with the humanised humoral immune system.